Pharma BD Deal Intelligence
AstraZeneca has found another potential gold nugget in China, this time offering as much as $2 billion to Jacobio Pharma to work on an early-stage pan-KRAS…
AstraZeneca strengthens China ties with planned $15B investment. The article references AstraZeneca's broader China strategy that includes the Jacobio Pharma…
AstraZeneca reaches $2 billion license agreement with Jacobio for pan-KRAS inhibitor JAB-23E73.
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AstraZeneca licensed a pan-KRAS inhibitor from Jacobio Pharma for global development and commercialization.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Jacobio Pharmaceuticals Group Co. Ltd. (this deal) | 2025 | $2.0B | 70 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2025 deals · AstraZeneca PLC deals · Oncology deals